Cyclic RGD Peptide Reduces Tumor Growth and Metastasis
Author Information
Author(s): Buerkle M A, Pahernik S A, Sutter A, Jonczyk A, Messmer K, Dellian M
Primary Institution: Ludwig-Maximilians-University, Munich, Germany
Hypothesis
The study investigates the effects of a methylated cyclic RGD-peptide as an αv-integrin antagonist on angiogenesis, growth, and metastasis of solid tumors in vivo.
Conclusion
Inhibition of αv-integrins by a cyclic RGD-peptide resulted in significant reduction of functional vessel density, retardation of tumor growth, and metastasis in vivo.
Supporting Evidence
- Functional vessel density was significantly reduced in treated animals compared to controls.
- Red blood cell velocity was lower in treated animals on day 3.
- Tumor growth was significantly delayed in RGD-treated animals compared to controls.
- Metastasis formation was significantly delayed in RGD-treated animals.
Takeaway
This study shows that a special peptide can help slow down the growth of tumors and stop them from spreading in hamsters.
Methodology
The study used male Syrian Golden hamsters with implanted tumors and treated them with a cyclic RGD-peptide, measuring various parameters of tumor growth and angiogenesis through intravital microscopy.
Limitations
The study was conducted in an animal model, which may not fully replicate human responses.
Participant Demographics
Male Syrian Golden hamsters, aged 6-8 weeks, weighing 50-60 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website